Argent Capital Management LLC acquired a new position in Catalent Inc (NYSE:CTLT) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 11,671 shares of the company’s stock, valued at approximately $466,000.

Several other hedge funds have also modified their holdings of CTLT. Zions Bancorporation purchased a new stake in Catalent during the third quarter valued at about $100,000. Acrospire Investment Management LLC raised its position in Catalent by 72.2% during the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock valued at $109,000 after purchasing an additional 1,300 shares in the last quarter. Quantbot Technologies LP raised its position in Catalent by 110.7% during the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock valued at $120,000 after purchasing an additional 1,804 shares in the last quarter. Fortaleza Asset Management Inc. purchased a new stake in Catalent during the third quarter valued at about $164,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Catalent by 12.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock valued at $177,000 after purchasing an additional 559 shares in the last quarter. Institutional investors own 99.49% of the company’s stock.

Catalent Inc (CTLT) opened at $40.02 on Thursday. Catalent Inc has a 12 month low of $25.51 and a 12 month high of $43.39. The stock has a market capitalization of $5,253.27, a PE ratio of 27.65, a PEG ratio of 2.54 and a beta of 1.41. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The firm had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $490.75 million. During the same period last year, the firm earned $0.16 earnings per share. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. sell-side analysts anticipate that Catalent Inc will post 1.46 EPS for the current fiscal year.

A number of equities research analysts have weighed in on CTLT shares. BidaskClub downgraded Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a research report on Tuesday, August 22nd. William Blair restated an “ourperform” rating on shares of Catalent in a research report on Tuesday, August 29th. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research report on Thursday, September 7th. Finally, Bank of America restated a “buy” rating and set a $40.00 price target (up previously from $38.00) on shares of Catalent in a research report on Tuesday, August 29th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Catalent has a consensus rating of “Buy” and an average price target of $44.44.

In other Catalent news, Director Uwe Roehrhoff bought 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The shares were bought at an average cost of $39.22 per share, with a total value of $294,150.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: This report was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/12/14/argent-capital-management-llc-acquires-new-stake-in-catalent-inc-ctlt.html.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.